The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies
Open accessAbstract
Apoptosis is a form of programmed cell death that results in the orderly and efficient removal of damaged cells, such as those resulting from DNA damage or during development. Apoptosis can be triggered by signals from within the cell, such as genotoxic stress, or by extrinsic signals, such as the binding of ligands to cell surface death receptors. Deregulation in apoptotic cell death machinery is an hallmark of cancer. Apoptosis alteration is responsible not only for tumor development and progression but also for tumor resistance to therapies. Most anticancer drugs currently used in clinical oncology exploit the intact apoptotic signaling pathways to trigger cancer cell death. Thus, defects in the death pathways may result in drug resistance so limiting the efficacy of therapies. Therefore, a better understanding of the apoptotic cell death signaling pathways may improve the efficacy of cancer therapy and bypass resistance. This review will highlight the role of the fundamental regulators of apoptosis and how their deregulation, including activation of anti-apoptotic factors (i.e., Bcl-2, Bcl-xL, etc) or inactivation of pro-apoptotic factors (i.e., p53 pathway) ends up in cancer cell resistance to therapies. In addition, therapeutic strategies aimed at modulating apoptotic activity are briefly discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887
De Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,136
The BCL-2 protein family: opposing activities that mediate cell death
Youle, R. J., & Strasser, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2308 · Cited by 4,679
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Mitochondrial membrane permeabilization in cell death
Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Apoptosis in cancer: from pathogenesis to treatment
Wong, R. S. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-87 · Cited by 2,836
Inhibition of death receptor signals by cellular FLIP
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,563
PUMA, a Novel Proapoptotic Gene, Is Induced by p53
Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,176
Noxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Programmed Cell Death in Animal Development and Disease
Fuchs, Y., & Steller, H. (2011) · Cell · doi:10.1016/j.cell.2011.10.033 · Cited by 1,915
IAP proteins: blocking the road to death's door
Salvesen, G. S., & Duckett, C. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm830 · Cited by 1,756
Caspase structure, proteolytic substrates, and function during apoptotic cell death
Nicholson, D. (1999) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400598 · Cited by 1,543
Morphologic and biochemical hallmarks of apoptosis
Saraste, A. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00384-3 · Cited by 1,466
Mechanisms of caspase activation
Boatright, K. M., & Salvesen, G. S. (2003) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2003.10.009 · Cited by 1,377
Transcriptional Activation of miR-34a Contributes to p53-Mediated Apoptosis
Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, Z., & Oren, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.017 · Cited by 1,352
Old, new and emerging functions of caspases
Shalini, S., Dorstyn, L., Dawar, S., & Kumar, S. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.216 · Cited by 1,267
Oda, K., Arakawa, H., Tanaka, T., Matsuda, K., Tanikawa, C., Mori, T., Nishimori, H., Tamai, K., Tokino, T., Nakamura, Y., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00073-8 · Cited by 1,172
Haupt, S., Berger, M., Goldberg, Z., & Haupt, Y. (2003) · Journal of Cell Science · doi:10.1242/jcs.00739 · Cited by 1,136
Degterev, A., Boyce, M., & Yuan, J. (2003) · Oncogene · doi:10.1038/sj.onc.1207107 · Cited by 1,107
Caspases in apoptosis and beyond
Li, J., & Yuan, J. (2008) · Oncogene · doi:10.1038/onc.2008.297 · Cited by 1,090
Lujambio, A., & Lowe, S. W. (2012) · Nature · doi:10.1038/nature10888 · Cited by 1,084
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,083
Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
Kang, M. H., & Reynolds, C. P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0144 · Cited by 1,016
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
Soengas, M. S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., McCombie, R., Herman, J. G., Gerald, W. L., Lazebnik, Y. A., et al. (2001) · Nature · doi:10.1038/35051606 · Cited by 966
Control of mitochondrial apoptosis by the Bcl-2 family
Brunelle, J. K., & Letai, A. (2009) · Journal of Cell Science · doi:10.1242/jcs.031682 · Cited by 929
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 1×
“The other half of human cancers express wildtype p53 protein that, however, can be inactivated by deregulation of regulatory proteins [130].”
Backgroundp53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death
Kroemer, G., El-Deiry, W. S., Golstein, P., Peter, M. E., Vaux, D., Vandenabeele, P., Zhivotovsky, B., Blagosklonny, M. V., Malorni, W., Knight, R. A., et al. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401724 · Cited by 843
Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S. Z., Huang, D. C. S., Xiong, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 830
Teitz, T., Wei, T., Valentine, M. B., Vanin, E. F., Grenet, J., Valentine, V. A., Behm, F. G., Look, A. T., Lahti, J. M., & Kidd, V. J. (2000) · Nature Medicine · doi:10.1038/75007 · Cited by 811
Häcker, G. (2000) · Cell and Tissue Research · doi:10.1007/s004410000193 · Cited by 801
Vousden, K. H. (2000) · Cell · doi:10.1016/s0092-8674(00)00171-9 · Cited by 790
Human Caspases: Activation, Specificity, and Regulation
Pop, C., & Salvesen, G. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r800084200 · Cited by 754
Cell Surface Trafficking of Fas: A Rapid Mechanism of p53-Mediated Apoptosis
Bennett, M., Macdonald, K., Chan, S.-W., Luzio, J. P., Simari, R., & Weissberg, P. (1998) · Science · doi:10.1126/science.282.5387.290 · Cited by 754
Hegde, R., Srinivasula, S. M., Zhang, Z., Wassell, R., Mukattash, R., Cilenti, L., DuBois, G., Lazebnik, Y., Zervos, A. S., Fernandes-Alnemri, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109721200 · Cited by 745
Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation
Brooks, C. L., & Gu, W. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00003-6 · Cited by 742
Folkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I. S., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 741
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
BAX activation is initiated at a novel interaction site
Gavathiotis, E., Suzuki, M., Davis, M. L., Pitter, K., Bird, G. H., Katz, S. G., Tu, H.-C., Kim, H., Cheng, E. H.-Y., Tjandra, N., et al. (2008) · Nature · doi:10.1038/nature07396 · Cited by 700
Life and death by death receptors
Guicciardi, M. E., & Gores, G. J. (2009) · The FASEB Journal · doi:10.1096/fj.08-111005 · Cited by 690
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis
D'Orazi, G., Cecchinelli, B., Bruno, T., Manni, I., Higashimoto, Y., Saito, S., Gostissa, M., Coen, S., Marchetti, A., Del Sal, G., et al. (2002) · Nature Cell Biology · doi:10.1038/ncb714 · Cited by 681
Self-citationMDM2 — master regulator of the p53 tumor suppressor protein
Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641
Vaseva, A. V., & Moll, U. M. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.10.005 · Cited by 618
Fulda, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24064 · Cited by 615
Apaf-1 is a transcriptional target for E2F and p53
Moroni, M. C., Hickman, E. S., Denchi, E. L., Caprara, G., Colli, E., Cecconi, F., Müller, H., & Helin, K. (2001) · Nature Cell Biology · doi:10.1038/35078527 · Cited by 593
PUMA mediates the apoptotic response to p53 in colorectal cancer cells
Yu, J., Wang, Z., Kinzler, K. W., Vogelstein, B., & Zhang, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2627984100 · Cited by 563
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
Almasan, A., & Ashkenazi, A. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00029-7 · Cited by 553
Raffo, A. J., Perlman, H., Chen, M., Day, M. L., Streitman, J., & Buttyan, R. (1995) · PubMed · Cited by 542
MDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532
IAP-targeted therapies for cancer
LaCasse, E. C., Mahoney, D. J., Cheung, H. H., Plenchette, S., Baird, S., & Korneluk, R. G. (2008) · Oncogene · doi:10.1038/onc.2008.302 · Cited by 524
Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice
Schimmer, A. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1918 · Cited by 512
Serial killers: ordering caspase activation events in apoptosis
Slee, E., Adrain, C., & Martin, S. (1999) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400601 · Cited by 473
Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462
BH3-only proteins in apoptosis and beyond: an overview
Lomonosova, E., & Chinnadurai, G. (2008) · Oncogene · doi:10.1038/onc.2009.39 · Cited by 458
BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death
Danial, N. N. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1598 · Cited by 433
Oakes, S. A., Scorrano, L., Opferman, J. T., Bassik, M. C., Nishino, M., Pozzan, T., & Korsmeyer, S. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408352102 · Cited by 428
BID regulation by p53 contributes to chemosensitivity
Sax, J. K., Fei, P., Murphy, M. E., Bernhard, E., Korsmeyer, S. J., & El-Deiry, W. S. (2002) · Nature Cell Biology · doi:10.1038/ncb866 · Cited by 420
Expression of bcl-xL can confer a multidrug resistance phenotype
Minn, A., Rudin, C., Boise, L., & Thompson, C. (1995) · Blood · doi:10.1182/blood.v86.5.1903.bloodjournal8651903 · Cited by 415 · cited 1×
“Such overexpression confers a multi-drug resistance phenotype in tumor cells and prevents them from undergoing apoptosis [63].”
BackgroundPERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family
Attardi, L. D., Reczek, E. E., Cosmas, C., Demicco, E. G., McCurrach, M. E., Lowe, S. W., & Jacks, T. (2000) · Genes & Development · doi:10.1101/gad.14.6.704 · Cited by 397
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression
Fulda, S., Meyer, E., & Debatin, K.-M. (2002) · Oncogene · doi:10.1038/sj.onc.1205258 · Cited by 394
Davies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., Jenkins, R., Cockerill, M., Cartlidge, S., & Smith, P. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0231 · Cited by 387
Dexheimer, T. S., Sun, D., & Hurley, L. H. (2006) · Journal of the American Chemical Society · doi:10.1021/ja0563861 · Cited by 383
Corcoran, R. B., Cheng, K. A., Hata, A. N., Faber, A. C., Ebi, H., Coffee, E. M., Greninger, P., Brown, R. D., Godfrey, J. T., Cohoon, T. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.007 · Cited by 377
To Trigger Apoptosis, Bak Exposes Its BH3 Domain and Homodimerizes via BH3:Groove Interactions
Dewson, G., Kratina, T., Sim, H. W., Puthalakath, H., Adams, J. M., Colman, P. M., & Kluck, R. M. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.005 · Cited by 348
Shimizu, S., Takehara, T., Hikita, H., Kodama, T., Miyagi, T., Hosui, A., Tatsumi, T., Ishida, H., Noda, T., Nagano, H., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.024 · Cited by 343
Caspases – controlling intracellular signals by protease zymogen activation
Stennicke, H. R., & Salvesen, G. S. (2000) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(99)00281-2 · Cited by 330
Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas.
Krajewska, M., Moss, S. F., Krajewski, S., Song, K. B., Holt, P. R., & Reed, J. C. (1996) · PubMed · Cited by 321
Discovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity
Tao, Z.-F., Hasvold, L., Wang, L., Wang, X., Petros, A. M., Park, C. H., Boghaert, E. R., Catron, N. D., Chen, J., Colman, P. M., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5001867 · Cited by 309
Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities
Plati, J., Bucur, O., & Khosravi‐Far, R. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21707 · Cited by 293
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
Baig, S., Seevasant, I., Mohamad, J., Mukheem, A., Huri, H. Z., & Kamarul, T. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.275 · Cited by 279
Sasaki, H., Sheng, Y., Kotsuji, F., & Tsang, B. K. (2000) · PubMed · Cited by 264
IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway
Fulda, S., & Debatin, K.-M. (2002) · Oncogene · doi:10.1038/sj.onc.1205255 · Cited by 260
MicroRNA regulation of core apoptosis pathways in cancer
Lima, R. T., Busacca, S., Almeida, G. M., Gaudino, G., Fennell, D. A., & Vasconcelos, M. H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.11.005 · Cited by 260
Holcik, M., Yeh, C., Korneluk, R. G., & Chow, T. (2000) · Oncogene · doi:10.1038/sj.onc.1203765 · Cited by 259
Tomita, Y., Marchenko, N., Erster, S., Nemajerova, A., Dehner, A., Klein, C., Pan, H., Kessler, H., Pancoska, P., & Moll, U. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507611200 · Cited by 248
Kojima, K., Konopleva, M., McQueen, T., O'Brien, S., Plunkett, W., & Andreeff, M. (2006) · Blood · doi:10.1182/blood-2005-12-5148 · Cited by 245
Targeting apoptosis for anticancer therapy
Fulda, S. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.002 · Cited by 231
Pepper, C., Hoy, T., & Bentley, D. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.487 · Cited by 230
BH3-only proteins and their roles in programmed cell death
Giam, M., Huang, D. C. S., & Bouillet, P. (2008) · Oncogene · doi:10.1038/onc.2009.50 · Cited by 229
Rossato, M., Curtale, G., Tamassia, N., Castellucci, M., Mori, L., Gasperini, S., Mariotti, B., De Luca, M., Mirolo, M., Cassatella, M. A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209100109 · Cited by 215
Abramson, J. S., & Shipp, M. A. (2005) · Blood · doi:10.1182/blood-2005-02-0687 · Cited by 208
Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Gimenez-Bonafe, P., Tortosa, A., & Perez-Tomas, R. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909788166600 · Cited by 196
Promises and Challenges of Smac Mimetics as Cancer Therapeutics
Fulda, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0365 · Cited by 194
Wang, P., Zhuang, L., Zhang, J., Fan, J., Luo, J., Chen, H., Wang, K., Liu, L., Chen, Z., & Meng, Z. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2012.10.011 · Cited by 186
Hengartner, M. O. (2001) · Cell · doi:10.1016/s0092-8674(01)00219-7 · Cited by 183
miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer
Sacconi, A., Biagioni, F., Canu, V, Mori, F., Di Benedetto, A., Lorenzon, L., Ercolani, C., Di Agostino, S., Cambria, A. M., Germoni, S., et al. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.160 · Cited by 180
Molecular Details of Bax Activation, Oligomerization, and Membrane Insertion
Bleicken, S., Classen, M., Padmavathi, P. V. L., Ishikawa, T., Zeth, K., Steinhoff, H.-J., & Bordignon, E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081539 · Cited by 176
Regulation of Apoptosis by Inhibitors of Apoptosis (IAPs)
Berthelet, J., & Dubrez, L. (2013) · Cells · doi:10.3390/cells2010163 · Cited by 174
Rinaldo, C., Prodosmo, A., Mancini, F., Iacovelli, S., Sacchi, A., Moretti, F., & Soddu, S. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.008 · Cited by 174
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease
Williams, J., Lucas, P. C., Griffith, K. A., Choi, M., Fogoros, S., Hu, Y. Y., & Liu, J. R. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.10.026 · Cited by 173
Bagnoli, M., Canevari, S., & Mezzanzanica, D. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.11.015 · Cited by 170
Huang, G., Nishimoto, K., Zhou, Z., Hughes, D., & Kleinerman, E. S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1460 · Cited by 165
Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity
Bruncko, M., Wang, L., Sheppard, G. S., Phillips, D. C., Tahir, S. K., Xue, J., Erickson, S., Fidanze, S., Fry, E., Hasvold, L., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501258m · Cited by 164
Li, Z., Huang, H., Chen, P., He, M., Li, Y., Arnovitz, S., Jiang, X., He, C., Hyjek, E., Zhang, J., et al. (2012) · Nature Communications · doi:10.1038/ncomms1681 · Cited by 164
Apoptotic threshold is lowered by p53 transactivation of caspase-6
MacLachlan, T. K., & El-Deiry, W. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132241599 · Cited by 162
Differential Inactivation of Caspase-8 in Lung Cancers
Shivapurkar, N., Toyooka, S., Eby, M. T., Huang, C. X., Sathyanarayana, U. G., Cunningham, H. T., Reddy, J. L., Brambilla, E., Takahashi, T., Minna, J. D., et al. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.1.45 · Cited by 160
Shirley, S., & Micheau, O. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.10.009 · Cited by 156
Amantana, A., London, C. A., Iversen, P. L., & Devi, G. R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.699.3.6 · Cited by 153
Mayo, L. D., Seo, Y. R., Jackson, M. W., Smith, M. L., Guzman, J. R., Korgaonkar, C. K., & Donner, D. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503026200 · Cited by 152
Michaud, W. A., Nichols, A. C., Mroz, E. A., Faquin, W. C., Clark, J. R., Begum, S., Westra, W. H., Wada, H., Busse, P. M., Ellisen, L. W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2581 · Cited by 151
Sonpavde, G., Matveev, V. B., Burke, J. M., Caton, J. R., Fleming, M. T., Hutson, T. E., Galsky, M. D., Berry, W. R., Karlov, P., Holmlund, J., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr555 · Cited by 149
Zhang, L., Dong, L.-Y., Li, Y., Hong, Z., & Wei, W. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-211 · Cited by 148
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
Han, B., Park, D., Li, R., Xie, M., Owonikoko, T. K., Zhang, G., Sica, G., Ding, C., Zhou, J., Magis, A. T., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.010 · Cited by 134
Thornborrow, E. C., Patel, S., Mastropietro, A. E., Schwartzfarb, E. M., & Manfredi, J. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205069 · Cited by 132
p53 downstream targets and chemosensitivity
Sax, J. K., & El‐Deiry, W. S. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401227 · Cited by 122
Zuzak, T. J., Steinhoff, D., Sutton, L. N., Phillips∥, P. C., Eggert, A., & Grotzer, M. A. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00355-0 · Cited by 110
Stefano, V. D., Rinaldo, C., Sacchi, A., Soddu, S., & D’Orazi, G. (2003) · Experimental Cell Research · doi:10.1016/j.yexcr.2003.09.032 · Cited by 104
Self-citationAssembling the building blocks: structure and function of inhibitor of apoptosis proteins
Mace, P. D., Shirley, S., & Day, C. L. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.45 · Cited by 101
Kojima, K., Konopleva, M. Y., Samudio, I. J., Schober, W. D., Bornmann, W. G., & Andreeff, M. (2006) · Cell Cycle · doi:10.4161/cc.5.23.3520 · Cited by 101
MicroRNA-608 and MicroRNA-34a Regulate Chordoma Malignancy by Targeting EGFR, Bcl-xL and MET
Zhang, Y., Schiff, D., Park, D. M., & Abounader, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091546 · Cited by 98
HIPK2 modulates p53 activity towards pro-apoptotic transcription
Puca, R., Nardinocchi, L., Sacchi, A., Rechavi, G., Givol, D., & D’Orazi, G. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-85 · Cited by 95
Self-citationBcl-2 interaction with the inositol 1,4,5-trisphosphate receptor: Role in Ca2+ signaling and disease
Distelhorst, C., & Bootman, M. D. (2011) · Cell Calcium · doi:10.1016/j.ceca.2011.05.011 · Cited by 88
Antiangiogenic Effect of TW37, a Small-Molecule Inhibitor of Bcl-2
Zeitlin, B. D., Joo, E., Dong, Z., Warner, K. A., Wang, G., Nikolovska‐Coleska, Z., Wang, S., & Nor, J. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3691 · Cited by 85
Therapeutic applications of TRAIL receptor agonists in cancer and beyond
Amarante-Mendes, G. P., & Griffith, T. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.09.001 · Cited by 83
Lin, J., Hou, J., Xiang, H.-D., Yan, Y., Gu, Y.-C., Tan, J., Li, D., Gu, L., Ou, T., & Huang, Z. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.12.040 · Cited by 83
Tourneur, L., Delluc, S., Lévy, V., Valensi, F., Radford‐Weiss, I., Legrand, O., Vargaftig, J., Boix, C., Macintyre, E. A., Varet, B. R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2361 · Cited by 83
Mancini, F., Conza, G. D., Pellegrino, M., Rinaldo, C., Prodosmo, A., Giglio, S., D’Agnano, I., Florenzano, F., Felicioni, L., Buttitta, F., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.154 · Cited by 83
Structural insights into the transcription-independent apoptotic pathway of p53
Chi, S. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.3.261 · Cited by 83
The origin of CD95-gene mutations in B-cell lymphoma
Müschen, M., Rajewsky, K., Krönke, M., & Küppers, R. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(01)02115-9 · Cited by 82
Pharmacological reactivation of p53 as a strategy to treat cancer
Zawacka‐Pankau, J., & Selivanova, G. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12336 · Cited by 82
Role of bax Mutations in Apoptosis in Colorectal Cancers With Microsatellite Instability
Miquel, C., Borrini, F., Grandjouan, S., Auperin, A., Viguier, J., Velasco, V., Duvillard, P., Praz, F., & Sabourin, J. (2005) · American Journal of Clinical Pathology · doi:10.1309/jq2x-3rv3-l8f9-tgyw · Cited by 80
Hata, A. N., Yeo, A., Faber, A. C., Lifshits, E., Chen, Z., Cheng, K. A., Walton, Z., Sarosiek, K. A., Letai, A., Heist, R. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3728 · Cited by 74
Kaposi's sarcoma tumor cells preferentially express Bcl-xL.
Foreman, K. E., Wrone-Smith, T., Boise, L., Thompson, C. B., Polverini, P. J., Simonian, P. L., Núñez, G., & Nickoloff, B. J. (1996) · Europe PMC (PubMed Central) · Cited by 72
HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function
Stefano, V. D., Blandino, G., Sacchi, A., Soddu, S., & D’Orazi, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207656 · Cited by 67
Self-citationTrisciuoglio, D., Gabellini, C., Desideri, M., Ragazzoni, Y., Luca, T. D., Ziparo, E., & Bufalo, D. D. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2010.175 · Cited by 67
Self-citationInhibitor of apoptosis proteins in hematological malignancies
Fulda, S. (2008) · Leukemia · doi:10.1038/leu.2008.329 · Cited by 67
Tourneur, L., Buzyn, A., & Chiocchia, G. (2005) · Medical Immunology · doi:10.1186/1476-9433-4-1 · Cited by 63
Small molecule compounds targeting the p53 pathway: are we finally making progress?
Yu, X., Narayanan, S., Vazquez, A., & Carpizo, D. R. (2014) · Apoptosis · doi:10.1007/s10495-014-0990-3 · Cited by 59
Expression and transcriptional regulation of caspase-14 in simple and complex epithelia
Pistritto, G., Jost, M., Srinivasula, S. M., Baffa, R., Poyet, J., Kari, C., Lazebnik, Y. A., Rodeck, U., & Alnemri, E. S. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401061 · Cited by 55
Self-citationSynthetic pre-microRNAs reveal dual-strand activity of miR-34a on TNF-α
Guennewig, B., Roos, M. M., Dogar, A. M., Gebert, L. F. R., Zagalak, J. A., Vongrad, V., Metzner, K. J., & Hall, J. (2013) · RNA · doi:10.1261/rna.038968.113 · Cited by 53
Stein, M. N., Hussain, M., Stadler, W. M., Liu, G., Tereshchenko, I. V., Goodin, S., Jeyamohan, C., Kaufman, H. L., Mehnert, J. M., & DiPaola, R. S. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2015.09.010 · Cited by 51
Targeting the MDM2/MDM4 Interaction Interface as a Promising Approach for p53 Reactivation Therapy
Pellegrino, M., Mancini, F., Lucà, R., Coletti, A., Giacchè, N., Manni, I., Arisi, I., Florenzano, F., Teveroni, E., Buttarelli, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0439 · Cited by 51
Yang, D. W., Chen, M., Wang, L., Yang, L., Liu, C., & Lu, P. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-105 · Cited by 51
HIF-1α antagonizes p53-mediated apoptosis by triggering HIPK2 degradation
Nardinocchi, L., Puca, R., & D’Orazi, G. (2011) · Aging · doi:10.18632/aging.100254 · Cited by 51
Self-citationMutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex
Garibaldi, F., Falcone, E., Trisciuoglio, D., Colombo, T., Lisek, K., Walerych, D., Sal, G. D., Paci, P., Bossi, G., Piaggio, G., et al. (2016) · Oncogene · doi:10.1038/onc.2016.51 · Cited by 51
Self-citationRinaldo, C., Prodosmo, A., Siepi, F., Moncada, A., Sacchi, A., Selivanova, G., & Soddu, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0337 · Cited by 50
Han, J., Hong, E. K., Choi, B. G., Park, J. N., Kim, K. W., Kang, J., Jin, J., Park, S. Y., Hong, Y. S., & Lee, K. S. (2003) · Medical Oncology · doi:10.1385/mo:20:4:355 · Cited by 49
BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death
Wade, M., Rodewald, L. W., Espinosa, J. M., & Wahl, G. M. (2008) · Cell Cycle · doi:10.4161/cc.7.13.6072 · Cited by 48
Mancini, F. R., Pieroni, L., Monteleone, V., Lucà, R., Fici, L., Luca, E., Urbani, A., Xiong, S., Soddu, S., Masetti, R., et al. (2015) · Oncogene · doi:10.1038/onc.2015.76 · Cited by 43
Otsuka, K., & Ochiya, T. (2014) · BioMed Research International · doi:10.1155/2014/749724 · Cited by 42
Garufi, A., Ubertini, V., Mancini, F., D’Orazi, V., Baldari, S., Moretti, F., Bossi, G., & D’Orazi, G. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0206-x · Cited by 41
Self-citationHigh glucose dephosphorylates serine 46 and inhibits p53 apoptotic activity
Garufi, A., & D’Orazi, G. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-014-0079-4 · Cited by 40
Self-citationPen, J. L., Laurent, M., Sarosiek, K. A., Vuillier, C., Gautier, F., Montessuit, S., Martinou, J., Letai, A. G., Braun, F., & Juin, P. P. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.400 · Cited by 40
Erović, B. M., Pelzmann, M., Grasl, M. C., Johannes, P., Kornek, G. V., Brannath, W., Selzer, E., & Thurnher, D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1170 · Cited by 39
Chiappori, A., Williams, C. C., Northfelt, D., Adams, J. W., Malik, S. M., Edelman, M. J., Rosen, P. J., Echo, D. A. V., Berger, M. S., & Haura, E. B. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000027 · Cited by 38
Trisciuoglio, D., Luca, T. D., Desideri, M., Passeri, D., Gabellini, C., Scarpino, S., Liang, C., Orlandi, A., & Bufalo, D. D. (2013) · Neoplasia · doi:10.1593/neo.121392 · Cited by 34
Self-citationOkamoto, K., Zaanan, A., Kawakami, H., Huang, S., & Sinicrope, F. A. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0476 · Cited by 31
Pistritto, G., Puca, R., Nardinocchi, L., Sacchi, A., & D’Orazi, G. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402186 · Cited by 30
Self-citationD’Orazi, G., Marchetti, A., Crescenzi, M., Coen, S., Sacchi, A., & Soddu, S. (2000) · The Journal of Gene Medicine · doi:10.1002/(sici)1521-2254(200001/02)2:1<11::aid-jgm81>3.0.co;2-k · Cited by 28
Self-citationFLIP: A flop for execution signals
Subramaniam, K., Hirpara, J. L., Tucker‐Kellogg, L., Tucker‐Kellogg, G., & Pervaiz, S. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.07.005 · Cited by 21
Nardinocchi, L., Puca, R., Givol, D., & D’Orazi, G. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.09.018 · Cited by 12
Self-citationAntagonizing Bcl-2′s BH4 domain in cancer
Vervloessem, T., Rovere, R. L., & Bultynck, G. (2015) · Aging · doi:10.18632/aging.100828 · Cited by 12
Phagocytosis of apoptotic cells by microglia in vitro
Bucur, O., Nat, R., Crețoiu, D., & Popescu, L. M. (2001) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2001.tb00181.x · Cited by 9
Combination therapy with p53–MDM2 binding inhibitors for malignancies
Jin, Z., Shen, J., He, J.-Y., & Hu, C. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1089-7 · Cited by 7
Theile, D., Allendorf, D. H., Köhler, B. C., Jassowicz, A., & Weiß, J. (2015) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12455 · Cited by 5
Cited by
The sirtuin family in health and disease
Wu, Q.-J., Zhang, T.-N., Chen, H.-H., Yu, X.-F., Lv, J.-L., Liu, Y.-Y., Liu, Y.-S., Zheng, G., Zhao, J.-Q., Wei, Y.-F., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01257-8 · Cited by 862
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 832
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Copper metabolism in cell death and autophagy
Xue, Q., Kang, R., Klionsky, D. J., Tang, D., Liu, J., & Chen, X. (2023) · Autophagy · doi:10.1080/15548627.2023.2200554 · Cited by 701
Hypoxia signaling in human health and diseases: implications and prospects for therapeutics
Luo, Z., Tian, M., Yang, G., Tan, Q., Chen, Y., Li, G., Zhang, Q., Li, Y., Wan, P., & Wu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01080-1 · Cited by 499
Metadata
- Authors
- Pistritto, G., Trisciuoglio, D., Ceci, C., Garufi, A., & D'Orazi, G.
- Venue
- Aging
- Publisher
- Impact Journals, LLC
- Published
- 2016-03-27
- Volume
- 8
- Issue
- 4
- Pages
- 603-619
- ISSN
- 1945-4589 (ISSN-L)
- OpenAlex
- W2408954743
- Cited by
- 1,658
- References
- 170
- FWCI
- 20.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.